Table 1

Characteristics of 35 HER2 negative mBC patients treated with Bevacizumab plus Paclitaxel followed by maintenance Bevacizumab
Total number of patients (n= 35) Frequency (%)
Median age (range) 50 (32–72)
Menopausal Status
 Pre 6 (17.1)
 Post 29 (82.9)
Hormonal Receptor Status
 Negative 5 (14.3)
  Positive 30 (85.7)
Triple negative 5 (14.3)
Adjuvant chemotherapy
- None 13 (37.1)
- including anthracyclines 9 (25.7)
- including antracyclines + taxanes 9 (25.7)
- Other regimens 4 (11.4)
Adjuvant hormonal therapy 22 (62.8)
Visceral metastatic sites 23 (65.7)
Median Disease Free Survival, months (range) 30 (0–362)
Median Cycles of Bevacizumab + Paclitaxel (range) 8 (6–12)
Median cycles of three-weekly mBev (range) 7 (1 – 28)
Median PS at the start of mBev (range) 0 (0–1)

PS, Performance Status (ECOG); Triple negative, estrogen receptor, progesteron receptor, HER2 negative; mBev, mainteinance Bevacizumab.

Fabi et al.

Fabi et al. BMC Cancer 2012 12:482   doi:10.1186/1471-2407-12-482

Open Data